CytRx Corporation (NASDAQ: CYTR) is permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate arimoclomol as ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE